Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kempharm Inc
(NQ:
KMPH
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 28, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
5.690 (8)
Ask (Size)
6.000 (20)
Prev. Close
5.810
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
33,932,639
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
February 22, 2023
From
KemPharm
Via
GlobeNewswire
KemPharm Announces Corporate Name Change to Zevra Therapeutics
February 22, 2023
From
KemPharm
Via
GlobeNewswire
Performance
More News
Read More
This Rare Disease Focused Stock Pipeline Is Underappreciated, Analyst Initiating Coverage Says
November 17, 2022
Via
Benzinga
KemPharm's Earnings: A Preview
November 08, 2022
Via
Benzinga
KemPharm's Lead Prodrug Shows Favorable Safety Profile For Rare Sleeping Disorder
September 28, 2022
Via
Benzinga
Recap: KemPharm Q2 Earnings
August 11, 2022
Via
Benzinga
KemPharm Acquires Battered Orphazyme's Arimoclomol Program For $13M
May 16, 2022
Via
Benzinga
KemPharm's SDX Higher Dose Shows Potential Against Sleep Disorders
March 21, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
November 17, 2022
Via
Benzinga
US Stocks Turn Lower; Nasdaq Drops Over 100 Points
September 15, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022
September 15, 2022
Via
Benzinga
Apple To $220? Here Are 5 Other Price Target Changes For Wednesday
August 17, 2022
Via
Benzinga
Recap: KemPharm Q1 Earnings
May 12, 2022
Via
Benzinga
Earnings Preview For KemPharm
May 11, 2022
Via
Benzinga
The Technology Helping Existing FDA-Approved Drugs Target More Effectively
May 03, 2022
Via
Benzinga
Benzinga Announces This Week's All Access Guests
April 28, 2022
Via
Benzinga
26 Stocks Moving in Monday's Pre-Market Session
April 25, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
March 31, 2022
Via
Benzinga
Earnings Scheduled For March 30, 2022
March 30, 2022
Via
Benzinga
KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder
January 20, 2022
Via
Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
March 27, 2022
Via
Benzinga
38 Stocks Moving In Monday's Mid-Day Session
December 20, 2021
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
February 16, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
January 31, 2022
Via
Benzinga
65 Biggest Movers From Yesterday
December 21, 2021
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.